Long-term observation of using high Selective beta1 receptor blockeron for stable COPD combined with hypertension

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17010892

Enrollment

Unknown

Registered

2017-03-16

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

study group: ß 1-blocker treatment

control:General treatment

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: According to GOLD2013 diagnostic criteria, there are dyspnea, chronic cough and expectoration, COPD risk factors, inhalation of bronchodilator lung function indicators FEV1 / FVC 140 / 90mmHg. With the patient fully informed after signing the consent form.

Exclusion criteria

Exclusion criteria: Suffering from active tuberculosis, bronchial asthma, pulmonary interstitial fibrosis, malignancy, acute infection, NYHA III above heart failure, poorly controlled diabetes, acute or chronic renal failure, systemic inflammatory disease, severe sinus tachycardia Slow heart rate of heart rate <50 beats / min), slow ventricular rate of atrial fibrillation (heart rate <70 beats / min), II degree 2 or more severe atrioventricular block, the expected survival of not more than 1 year of other diseases Except for patients.

Design outcomes

Primary

Measure	Time frame
LVEF;Oxygen saturation;FEVI/FVC;	—

Countries

China

Contacts

Public ContactHaiying Yan

Sichuan Provincial People's Hospital

yanhaiying8295@163.com+86 18981838295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026